0 CHECKOUT

Liver Cirrhosis - Pipeline Review, H2 2015

  • ID: 3448660
  • September 2015
  • 104 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Alfa Wassermann S.p.A
  • Digna Biotech, S.L.
  • Gilead Sciences, Inc.
  • GNI Group Ltd.
  • Nimbus Therapeutics, LLC
  • PharmaIN Corporation
  • MORE

Liver Cirrhosis - Pipeline Review, H2 2015

Summary

The report ‘Liver Cirrhosis - Pipeline Review, H2 2015’, provides an overview of the Liver Cirrhosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alfa Wassermann S.p.A
  • Digna Biotech, S.L.
  • Gilead Sciences, Inc.
  • GNI Group Ltd.
  • Nimbus Therapeutics, LLC
  • PharmaIN Corporation
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Liver Cirrhosis Overview

Therapeutics Development

Pipeline Products for Liver Cirrhosis - Overview

Pipeline Products for Liver Cirrhosis - Comparative Analysis

Liver Cirrhosis - Therapeutics under Development by Companies

Liver Cirrhosis - Therapeutics under Investigation by Universities/Institutes

Liver Cirrhosis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Liver Cirrhosis - Products under Development by Companies

Liver Cirrhosis - Products under Investigation by Universities/Institutes

Liver Cirrhosis - Companies Involved in Therapeutics Development

Alfa Wassermann S.p.A

Conatus Pharmaceuticals Inc.

Digna Biotech, S.L.

Galectin Therapeutics, Inc.

Gilead Sciences, Inc.

GNI Group Ltd.

Human Stem Cells Institute

Nimbus Therapeutics, LLC

PharmaIN Corporation

Pharmicell Co., Ltd.

S-Evans Biosciences, Inc.

Stelic Institute & Co.

Stempeutics Research Private Limited

Liver Cirrhosis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(sofosbuvir + velpatasvir) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DB-027 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DB-036 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism of Action

R&D Progress

F-351 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gemacell - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GR-MD-01 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GR-MD-02 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GXHPC-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Livercellgram - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Cirrhosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ND-654 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Px-104 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rifaximin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

simtuzumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stempeucel - Drug Profile

Product Description

Mechanism of Action

R&D Progress

STNM-04 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

thrombopoietin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Undisclosed Peptide for Liver Cirrhosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Liver Cirrhosis - Recent Pipeline Updates

Liver Cirrhosis - Dormant Projects

Liver Cirrhosis - Discontinued Products

Liver Cirrhosis - Product Development Milestones

Featured News & Press Releases

Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement

May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam

Mar 25, 2015: NICE recommends treatment for brain condition caused by liver failure

Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting

Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting

Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension

Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis

Jan 20, 2011: Stempeutics Research's Stempeucel LC Recieves DCGI Clearance To Start Phase II Clinical Trial For Liver Cirrhosis

Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNI’s Key Therapeutic Product for Liver Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Liver Cirrhosis, H2 2015

Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Liver Cirrhosis - Pipeline by Alfa Wassermann S.p.A, H2 2015

Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc., H2 2015

Liver Cirrhosis - Pipeline by Digna Biotech, S.L., H2 2015

Liver Cirrhosis - Pipeline by Galectin Therapeutics, Inc., H2 2015

Liver Cirrhosis - Pipeline by Gilead Sciences, Inc., H2 2015

Liver Cirrhosis - Pipeline by GNI Group Ltd., H2 2015

Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H2 2015

Liver Cirrhosis - Pipeline by Nimbus Therapeutics, LLC, H2 2015

Liver Cirrhosis - Pipeline by PharmaIN Corporation, H2 2015

Liver Cirrhosis - Pipeline by Pharmicell Co., Ltd., H2 2015

Liver Cirrhosis - Pipeline by S-Evans Biosciences, Inc., H2 2015

Liver Cirrhosis - Pipeline by Stelic Institute & Co., H2 2015

Liver Cirrhosis - Pipeline by Stempeutics Research Private Limited, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Liver Cirrhosis Therapeutics - Recent Pipeline Updates, H2 2015

Liver Cirrhosis - Dormant Projects, H2 2015

Liver Cirrhosis - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Liver Cirrhosis, H2 2015

Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Alfa Wassermann S.p.A
Conatus Pharmaceuticals Inc.
Digna Biotech, S.L.
Galectin Therapeutics, Inc.
Gilead Sciences, Inc.
GNI Group Ltd.
Human Stem Cells Institute
Nimbus Therapeutics, LLC
PharmaIN Corporation
Pharmicell Co., Ltd.
S-Evans Biosciences, Inc.
Stelic Institute & Co.
Stempeutics Research Private Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Novartis AG
  • Abbott Laboratories Ltd.
  • GlaxoSmithKline PLC
  • Sanofi S.A.
  • Actavis
  • Genfit